Stock Events

Stock Events

Biomarin Pharmaceutical 

$66.53
212
+$0.10+0.15% 20:00 Today
+$0.47+0.71%21:53After hours

Statistics

Day High
66.56
Day Low
65.71
52W High
70.98
52W Low
49.26
Volume
53,515
Avg. Volume
-
Mkt Cap
12.88B
P/E Ratio
42.53
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.28
0.26
0.8
1.34
Expected EPS
1.337792
Actual EPS
N/A

Financials

10.83%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.22BRevenue
348.9MNet Income

Analyst Ratings

92.00Average Price Target
The highest estimate is 124.00.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
79%
Hold
21%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BMRN. It's not an investment recommendation.
Microsoft
50
MSFT
Amazon
49
AMZN
Apple
48
AAPL
NVIDIA
47
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals competes in the cystic fibrosis market, where both companies are looking for treatments that address the underlying cause of genetic diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in genetic disorder treatments among other areas, competing with Biomarin in the broader biotech space.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse biotech portfolio that includes treatments for genetic disorders, making it a competitor in the biopharmaceutical field.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its focus on antiviral drugs and other treatments, competes for market share in the biopharmaceutical industry.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk specializes in diabetes and obesity treatments but is expanding into biopharmaceuticals for genetic diseases, competing with Biomarin.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio that includes a focus on rare diseases, making it a competitor in the same space as Biomarin.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurological disorders and rare diseases, areas where Biomarin also seeks to make an impact, making them direct competitors.

About

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Show more...
CEO
Alexander Hardy
Employees
3221
Country
United States
ISIN
US09061G1013
WKN
000924801

Listings

MI
IT
1BMRN.MI
MU
DE
BM8.MU
XNAS
US
BMRN
STU
DE
BM8.STU

0 Comments

Share your thoughts

FAQ

What is Biomarin Pharmaceutical stock price today?▼
The current price of BMRN is $66.53 USD — it has increased by +0.15% in the past 24 hours. Watch Biomarin Pharmaceutical stock price performance more closely on the chart.
What is Biomarin Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Biomarin Pharmaceutical stocks are traded under the ticker BMRN.
Is Biomarin Pharmaceutical stock price growing?▼
BMRN stock has risen by +2.88% compared to the previous week, the month change is a +9.57% rise, over the last year Biomarin Pharmaceutical has showed a +17.23% increase.
What is Biomarin Pharmaceutical market cap?▼
Today Biomarin Pharmaceutical has the market capitalization of 12.88B
When is the next Biomarin Pharmaceutical earnings date?▼
Biomarin Pharmaceutical is going to release the next earnings report on November 03, 2026.
What were Biomarin Pharmaceutical earnings last quarter?▼
BMRN earnings for the last quarter are 1.2 USD per share, whereas the estimation was 0.95 USD resulting in a +26.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biomarin Pharmaceutical revenue for the last year?▼
Biomarin Pharmaceutical revenue for the last year amounts to 3.22B USD.
What is Biomarin Pharmaceutical net income for the last year?▼
BMRN net income for the last year is 348.9M USD.
How many employees does Biomarin Pharmaceutical have?▼
As of September 04, 2026, the company has 3,221 employees.
In which sector is Biomarin Pharmaceutical located?▼
Biomarin Pharmaceutical operates in the Health & Wellness sector.
When did Biomarin Pharmaceutical complete a stock split?▼
Biomarin Pharmaceutical has not had any recent stock splits.
Where is Biomarin Pharmaceutical headquartered?▼
Biomarin Pharmaceutical is headquartered in NOVATO, United States.